

# Claims

1. Substantially purified form of the polypeptide that comprising the amino-acid sequence shown in SEQ ID NO. 11 or 14, homologue thereof, fragment thereof or homologue of the fragment.

2. A polypeptide according to claim 1 that consists (comprising) of the amino-acid sequence shown in SEQ ID NO. 11 or 14.

3. A cDNA encoding the polypeptide according to claim 1.

4. A cDNA according to claim 3 that comprising the nucleotide sequence shown in SEQ ID NO. 12 or 15 or a fragment cDNA selectively hybridized to the cDNA.

5. A cDNA according to claim 3 that comprising the nucleotide sequence shown in SEQ ID NO. 13 or a fragment cDNA selectively hybridized to the cDNA.

6. A replication or expression vector carrying the cDNA according to claim 3 to 5.

7. A host cell transformed with the replication or expression vector according to claim 6.

8. A method for producing the polypeptide according to claim 1 or 2 which comprises culturing a host cell according to claim 7 under a condition effective to express the polypeptide according to claim 1 or 2.

9. A monoclonal or polyclonal antibody against the polypeptide according to claim 1 or 2.

10. A pharmaceutical composition containing the polypeptide according to claim 1 or 2 or the antibody according to claim 9, in association with pharmaceutically acceptable diluent and/or carrier.

11. A pharmaceutical composition for the treatment of abnormal growth of smooth muscle cell, containing a polypeptide according to claim 1 or 2, in association with a pharmaceutically acceptable diluent and/or

carrier.

12. A pharmaceutical composition for the treatment of arteriosclerosis, restenosis after PTCA or myosarcoma, containing the polypeptide according to claim 1 or 2, in association with a pharmaceutically acceptable diluent and/or carrier.

13. A screening method for an antagonist or agonist of the polypeptide according to claim 1 or 2 with using the said polypeptide.

add B17